Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

(2010) S. N. Khleif et al.   CLINICAL CANCER RESEARCH

Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot

(2010) Ann A. Lazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

(2009) Anita Giobbie-Hurder et al.   Clinical Trials

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

Epidemiologic Study of In-Hospital Cardiopulmonary Resuscitation in the Elderly

(2009) William J. Ehlenbach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY